Pathogenesis of Dengue virus in Host immune system and its genomic variation

Abstract

Dengue viruses are the most prevalent arthropod-borne viral diseases in humans, infecting 50-100 million people each year. Its serotypes are the most common causes of arboviral illness, putting half of the world's population at risk of infection. Because there is no vaccine or antiviral medicines, the only way to manage the disease is to reduce the Aedes mosquito vectors. DENV infection can be asymptomatic or cause a self-limiting, acute febrile illness with varying degrees of severity. High fever, headache, stomach discomfort, rash, myalgia, and arthralgia are the typical symptoms of dengue fever (DF). Thrombocytopenia, vascular leakage, and hypotension are symptoms of severe dengue, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Systemic shock characterizes DSS, which can be deadly. Dengue virus infection pathogenesis is linked to a complex interaction between virus, host genes, and host immune response. Major drivers of disease vulnerability include host factors such as antibody-dependent enhancement (ADE), memory cross-reactive T cells, anti-DENV NS1 antibodies, autoimmunity, and genetic variables. The NS1 protein and anti-DENV NS1 antibodies were thought to be involved in the development of severe dengue. The progressive infection may change the cytokine response of cross reactive CD4+ T cells. The need for dengue vaccines that can generate strong protective immunity against all four serotypes is required. To create such vaccines, a thorough understanding of DENV adaptive immunity is required. Structural and functional research have shown that the degree of prM protein cleavage as well as the ensemble of conformational states sampled by virions influence DENV sensitivity to antibody-mediated neutralization, which has crucial implications for vaccine formulation.

GC-MS Based Characterization, Antibacterial, Antifungal and Anti-Oncogenic Activity of Ethyl Acetate Extract of Aspergillus niger Strain AK-6 Isolated from Rhizospheric Soil

“…More than 500 antibiotics are discovered yearly; however, almost 60% are obtained from the soil, this thereby representing the most critical reservoir for novel antibiotics with pharmaceutical and biological activity [43]. An investigation by Sohail et al (2014) reported the antimicrobial potential of acetonitrile and nhexane extracts of the R. stolonifer against some fungal and bacterial pathogenic strains [44]. In this study, the acetonitrile extract of R. stolonifera inhibited several fungal pathogenic strains such as A. niger, A. oryzae, C. albicans, P. digitatum and F. oxysporum, and the bacterial pathogens P. aeruginosa, E. coli, S. aureus, S. aureus (methicillin-resistant) and S. aureus (vancomycin-resistant), more effectively than the n-hexane extract.…”